KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Leases (2019 - 2025)

Arbutus Biopharma (ABUS) has disclosed Current Leases for 10 consecutive years, with $547000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases rose 13.25% to $547000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $547000.0 through Dec 2025, up 13.25% year-over-year, with the annual reading at $547000.0 for FY2025, 13.25% up from the prior year.
  • Current Leases hit $547000.0 in Q4 2025 for Arbutus Biopharma, up from $531000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $563000.0 in Q1 2025 to a low of $357000.0 in Q2 2021.
  • Historically, Current Leases has averaged $442350.0 across 5 years, with a median of $435500.0 in 2021.
  • Biggest five-year swings in Current Leases: fell 6.74% in 2022 and later grew 14.44% in 2023.
  • Year by year, Current Leases stood at $383000.0 in 2021, then fell by 2.87% to $372000.0 in 2022, then increased by 14.25% to $425000.0 in 2023, then increased by 13.65% to $483000.0 in 2024, then increased by 13.25% to $547000.0 in 2025.
  • Business Quant data shows Current Leases for ABUS at $547000.0 in Q4 2025, $531000.0 in Q3 2025, and $514000.0 in Q2 2025.